{"id":12162,"date":"2023-11-01T23:42:00","date_gmt":"2023-11-01T15:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=12162"},"modified":"2024-11-11T23:48:33","modified_gmt":"2024-11-11T15:48:33","slug":"shanghais-argo-biopharma-raises-usd-41-million-in-series-a-financing-round","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12162","title":{"rendered":"Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round"},"content":{"rendered":"\n

Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma’s four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.<\/p>\n\n\n\n

Global Development and Pipeline Expansion<\/strong>
The proceeds from the Series A+ financing will play a crucial role in ramping up the global development of Argo Biopharma’s clinical pipelines. The company is committed to advancing its drug candidates through various stages of clinical development, with a focus on addressing unmet medical needs in cardiovascular disease, rare diseases, hepatitis B, autoimmune diseases, nervous system disorders, and more.<\/p>\n\n\n\n

Clinical Approvals and Company Milestones<\/strong>
Since its founding in 2021, Argo Biopharma has made significant strides, boasting four pipeline candidates at clinical stages and one entering the clinic. The company has received clinical trial approvals in China, the United States, and Australia, marking a significant milestone in its journey to bring innovative siRNA therapies to patients worldwide.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1711],"class_list":["post-12162","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-argo-biopharma"],"yoast_head":"\nShanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma's four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12162\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12162\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-01T15:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T15:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round\",\"datePublished\":\"2023-11-01T15:42:00+00:00\",\"dateModified\":\"2024-11-11T15:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Argo Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12162#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12162\",\"name\":\"Shanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-01T15:42:00+00:00\",\"dateModified\":\"2024-11-11T15:48:33+00:00\",\"description\":\"Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma's four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12162\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12162#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round - Insight, China's Pharmaceutical Industry","description":"Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma's four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12162","og_locale":"en_US","og_type":"article","og_title":"Shanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12162","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-01T15:42:00+00:00","article_modified_time":"2024-11-11T15:48:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12162#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12162"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round","datePublished":"2023-11-01T15:42:00+00:00","dateModified":"2024-11-11T15:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12162"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Argo Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12162#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12162","url":"https:\/\/flcube.com\/?p=12162","name":"Shanghai's Argo Biopharma Raises USD 41 Million in Series A+ Financing Round - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-01T15:42:00+00:00","dateModified":"2024-11-11T15:48:33+00:00","description":"Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma's four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12162#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12162"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12162#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12162"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12162\/revisions"}],"predecessor-version":[{"id":12164,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12162\/revisions\/12164"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}